Mizuho lowered the firm’s price target on Acadia Pharmaceuticals to $21 from $25 and keeps a Neutral rating on the shares. The company’s Q1 results were mixed as the bottom-line modestly beat, while the top line slightly missed, the analyst tells investors in a research note. The firm says investors will likely be disappointed by Q1 Daybue sales of $75.9M, which modestly missed consensus’ lower reset expectation of $79.0M.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD:
- ACAD Earnings this Week: How Will it Perform?
- Acadia Pharmaceuticals announces Health Canada acceptance of trofinetide NDS
- Acadia Pharmaceuticals to present trofinetide findings in Rett syndrome at AAN
- Largest borrow rate increases among liquid names
- Acadia Pharmaceuticals price target lowered to $25 from $29 at JPMorgan
